Living our Passion for the Patient

2017 crr cover, Passion for the PatientAt Celgene, we have a deep and abiding passion for the patients we serve. This is our core attribute and a significant responsibility, which the people of Celgene take very seriously in their work each day. Celgene’s 2017 Corporate Responsibility Report, released this week, demonstrates how Celgene continually strives to realize our passion for the patient, as well as support our employees, communities and the well-being of the environment.

Celgene is a science-based company that creates value for all stakeholders when we fulfill our mission to develop medicines that improve and extend the lives of patients today, while investing in cures for the future. “Celgene’s innovative therapies offer hope to patients with significant medical needs,” said Mark J. Alles, CEO of Celgene. “We are therefore focused on how we can make these medicines accessible for the patients who need them.”

In 2016 alone, more than 500,000 patients were treated with Celgene therapies. In doing so, we are fulfilling our purpose — to change the course of human health through bold pursuits in science, and a promise to always put patients first.

As a founding member of Access Accelerated, a partnership of 23 biopharmaceutical companies, Celgene is working to create innovative and sustainable solutions to help improve access to treatment and care for non-communicable diseases, such as cancer, in low-and middle-income countries. Understanding that collaboration is key to making measurable progress, we’re working across health systems and sectors, and supporting the achievement of the UN Sustainable Development Goals.

Celgene, working together with our partners and collaborators, applies expertise and resources to help build health care capacity and access in under-resourced countries to help combat a growing incidence of cancer and other diseases. That’s why we actively support a consortium of academic health centers, called the Academic Model Providing Access to Healthcare (AMPATH), which focuses on improving the health of low-income populations in Kenya and achieving a replicable model for addressing the short and long-term challenges of global health.

To support local communities, Celgene and its employees lend time, care and expertise to numerous initiatives and organizations each year. Celgene supports roughly 50 organizations in the U.S., and through Community Health Charities, provides employees with the opportunity to donate to causes and charities via a payroll deduction. During the 2016 Light The Night® Walk, a fundraising campaign that benefits the Leukemia & Lymphoma Society (LLS) and their research, 1,028 people walked on 63 Celgene teams, making Celgene the number one Light the Night biopharmaceutical partner with contributions totaling over $627,000.

To help shape a sustainable environment for generations to come, Celgene is also committed to best practices in environmental stewardship, including working to achieve the quantifiable 2020 environmental goals we established in 2016 for greenhouse gas emissions, renewable electricity, water withdrawal and solid waste. Last year, we achieved more than 50 percent of electricity use through certified renewable sources and diverted more than 40 percent of waste to recycling and recovery efforts.  These efforts were recently recognized through Celgene’s ranking as number seven among all U.S. companies, and the top health care company, in the Newsweek Green Rankings for 2017.

At Celgene, we strive to put patients first in everything we do,” said Zeba Khan, Vice President of Corporate Responsibility. “We constantly look for new ways we can make a unique and tangible difference in people’s lives, both in terms of access to lifesaving treatments and by contributing to a sustainable future.”

To read the 2017 Celgene Corporate Responsibility Report, please click here.